<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15935019
   </pmid>
   <datecreated>
    <year>
     2005
    </year>
    <month>
     06
    </month>
    <day>
     06
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2005
    </year>
    <month>
     08
    </month>
    <day>
     16
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2008
    </year>
    <month>
     03
    </month>
    <day>
     10
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0002-8614
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       53
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <year>
        2005
       </year>
       <month>
        Jun
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of the American Geriatrics Society
     </title>
     <isoabbreviation>
      J Am Geriatr Soc
     </isoabbreviation>
    </journal>
    <articletitle>
     The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial.
    </articletitle>
    <pagination>
     <medlinepgn>
      970-5
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      To provide preliminary evidence on the effectiveness and optimal dosage of megestrol acetate for older persons with impaired appetite after hospitalization.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Randomized clinical trial.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Acute care hospital.
     </abstracttext>
     <abstracttext label="PARTICIPANTS" nlmcategory="METHODS">
      Forty-seven older persons (mean age 83) who were recently discharged from an acute care hospital and had fair or poor appetite.
     </abstracttext>
     <abstracttext label="INTERVENTION" nlmcategory="METHODS">
      Participants were randomized to placebo or megestrol acetate suspension 200 mg, 400 mg, or 800 mg daily for 9 weeks.
     </abstracttext>
     <abstracttext label="MEASUREMENTS" nlmcategory="METHODS">
      Appetite, health-related quality of life, and adverse effects were measured at baseline and 20, 42, and 63 days. Serum nutritional markers were measured at baseline and 20 and 63 days.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      During the course of the study, there were no significant differences between treatment groups on any of the appetite questions, although participants in the 400-mg and 800-mg groups demonstrated significant improvement from baseline on some questions. At 20 days, prealbumin increased in a dose-response relationship across the four groups (by 0.4, 5.1, 7.5, and 9.0 mg/dL, respectively). Participants in the 400-mg and 800-mg groups demonstrated greater improvement in prealbumin levels at 20 days than those receiving placebo (P=.009 and P=.004, respectively) and those in the 400-mg group also demonstrated improvement at 63 days (P=.02). At 20 days, no participant taking placebo had a morning serum cortisol level less than 8 ng/mL (the lower limit of normal). In contrast, 33%, 70%, and 78% of those taking 200 mg, 400 mg and 800 mg, respectively, had values below this level; by 63 days, these percentages were 11%, 30%, 56%, and 37%, respectively. No patient reported clinical symptoms of adrenal insufficiency. Diarrhea developed in three subjects, and thromboembolism occurred in two receiving active treatment.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Megestrol acetate at doses of 400 mg and 800 mg increases prealbumin in recently hospitalized older persons. Cortisol suppression is common at higher doses and may be persistent. In this small study, the drug did not confer benefit on other nutritional or clinical outcomes.
     </abstracttext>
    </abstract>
    <affiliation>
     UCLA Multicampus Program in Geriatric Medicine and Gerontology, University of California at Los Angeles, Los Angeles, California 90095, USA. dreuben@mednet.ucla.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Reuben
      </lastname>
      <forename>
       David B
      </forename>
      <initials>
       DB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hirsch
      </lastname>
      <forename>
       Susan H
      </forename>
      <initials>
       SH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Zhou
      </lastname>
      <forename>
       Kefei
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Greendale
      </lastname>
      <forename>
       Gail A
      </forename>
      <initials>
       GA
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Clinical Trial, Phase II
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     J Am Geriatr Soc
    </medlineta>
    <nlmuniqueid>
     7503062
    </nlmuniqueid>
    <issnlinking>
     0002-8614
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Appetite Stimulants
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Serum Albumin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Suspensions
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-23-7
     </registrynumber>
     <nameofsubstance>
      Hydrocortisone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      51154-23-5
     </registrynumber>
     <nameofsubstance>
      Megestrol Acetate
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Am Geriatr Soc. 2006 Jan;54(1):172-3; author reply 173-4
     </refsource>
     <pmid version="1">
      16420220
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Am Geriatr Soc. 2006 Mar;54(3):548; author reply 548-9
     </refsource>
     <pmid version="1">
      16551332
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Am Geriatr Soc. 2006 Jan;54(1):173; author reply 173-4
     </refsource>
     <pmid version="1">
      16420222
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Oral
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Appetite
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Appetite Stimulants
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dose-Response Relationship, Drug
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Eating Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Hospitalization
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydrocortisone
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Megestrol Acetate
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Nutrition Assessment
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serum Albumin
     </descriptorname>
     <qualifiername majortopicyn="N">
      analysis
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Suspensions
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2005
     </year>
     <month>
      6
     </month>
     <day>
      7
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2005
     </year>
     <month>
      8
     </month>
     <day>
      17
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2005
     </year>
     <month>
      6
     </month>
     <day>
      7
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     JGS53307
    </articleid>
    <articleid idtype="doi">
     10.1111/j.1532-5415.2005.53307.x
    </articleid>
    <articleid idtype="pubmed">
     15935019
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

